All posts related to "psoriatic arthritis"

Phil Mickelson misses Rio 2016 but swings psoriatic arthritis into remission

A golfer taking a swing on a golf course - psoriatic arthritisProfessional golfer Phil Mickelson was diagnosed with psoriatic arthritis in 2010. At first, his joints ached and then one day, he could barely get out of bed due to agonizing pain. While he waited for test results from his rheumatologist, he played in the 2010 U.S. Open and landed a fourth place finish.

If untreated, psoriatic arthritis can affect Mickelson’s golf game. The swelling of the hands and toes can affect his ability to stabilize his swing and stance. Swelling in the hands can also affect how he grips his club. With the help of medications, Mickelson is back in the game. Off the golf course, he is a vocal advocate of raising awareness for arthritis.  Continue reading

Correction to July 12’s JointHealth™ insight

Correction for apremilast (Otezla®) listing in the Ontario drug formulary

A reference in the July 12, 2016 online publication of JointHealth™ insight referred incorrectly to the listing of apremilast (Otezla®) for the treatment of psoriatic arthritis in the Ontario drug formulary as “declined.” The medication should be listed as “under review” as it is still under consideration for reimbursement.

Click here to see the updated Report Card.

We want to hear from you. If you have been affected by the delayed review of apremilast (Otezla®), please contact us at feedback@jointhealth.org.

JointHealth™ insight: The latest news on provincial drug formulary

In this issue of JointHealth™ insight, Arthritis Consumer Experts (ACE) maps out the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies and what it means for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA).

Map of Canada with highlights of changesManitoba
The following medication has been listed for reimbursement on the provincial drug formulary: Continue reading

JointHealth™ insight – Medications Guide Edition, June 2016

State of Arthritis Medications: Some old, some new, all important

JointHealth Meds Slide for 2016The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.

The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.

In this JointHealth™ insight, you will also find:

  • An explanation of the naming changes in the different categories of
    arthritis medications
  • Insight into the patient-physician therapy conversation by Cheryl Koehn, Founder and President of Arthritis Consumer Experts
  • Updated disease information for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, and lupus
  • The latest research on methotrexate and the consumption of alcoholic beverages

 

Let BC PharmaCare hear “Your Voice” on secukinumab

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on secukinumab for the treatment of ankylosing spondylitis and psoriatic arthritis

Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about secukinumab for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

You can give input if you are a B.C. resident and have AS or PsA, a caregiver to someone with AS or PsA, or if your group represents people who live with AS or PsA.

The submission deadline is midnight on July 21, 2016. Patients and caregivers may give their input directly through the links below.
Continue reading

The lastest provincial listings, at your fingertips

Map of Canada

(Please click on the map for more information about the provincial drug formulary updates.)

The latest provincial listings, at your fingertips

Good news for people living with autoimmune arthritis in Canada!

Arthritis Consumer Experts (ACE) maps out the latest news for you: Read about the important changes to provincial drug formularies and what it means for Canadians living with autoimmune arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Continue reading